Introduction to Received Intravitreal Brolucizumab

Sentence Examples

Learn more from Received Intravitreal Brolucizumab

Received Intravitreal Brolucizumab sentence examples

10.3390/jcm10112425

All patients received intravitreal brolucizumab as primary or switch therapy.

Brolucizumab for Choroidal Neovascular Membrane with Pigment Epithelial Tear and Subretinal Fluid

10.1007/s40278-021-95700-9

The woman with a known medical history of an allergy to tropicamide ophthalmic solution, received intravitreal brolucizumab injection for polypoidal choroidal vasculopathy OD.

Aflibercept/brolucizumab

Learn more from Received Intravitreal Brolucizumab

An Overview of Received Intravitreal Brolucizumab

Received Intravitreal Brolucizumab
Encyclopedia

What is/are Intravitreal Brolucizumab?

Intravitreal Brolucizumab - The patient was shifted to intravitreal Brolucizumab. [1] All patients were treated with intravitreal brolucizumab 6mg between November 2020 and May 2021. [2] CONCLUSION Intravitreal brolucizumab treatment can achieve significant reductions particularly of SRF and sub-RPE in patients refractory to previous anti-VEGF treatment. [3] Interventions: A combination therapy involving of intravitreal brolucizumab and STTA Outcomes: The anti-vascular endothelial growth factor inhibitor was changed back to aflibercept; however, exudation persisted. [4] Patients received 3 monthly intravitreal aflibercept (n = 38) or intravitreal brolucizumab (n = 14). [5] Although the serous retinal detachment (SRD) disappeared after IVA treatment, the patient was managed with treatment every 4 weeks without extending the treatment interval To shorten the treatment interval, intravitreal brolucizumab (IVBr) was started 44 weeks after starting IVA treatment. [6] Recently, she had been switched to intravitreal brolucizumab injection. [7]

neovascular age related

Case 2: An 82-year-old man who had neovascular age-related macular degeneration, received the first dose of intravitreal brolucizumab injection OD. [1] We evaluated the efficacy and safety of loading phase treatment with intravitreal brolucizumab for neovascular age-related macular degeneration (nAMD) with type 1 choroidal neovascularization (CNV). [2] The aim of the present study was to determine the efficacy and safety of intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) in the real-world setting. [3] Purpose To assess the short-term efficacy and safety profile of intravitreal brolucizumab injection in Indian eyes with neovascular age-related macular degeneration (nAMD) under real-world conditions. [4] The present study aimed to determine the efficacy and safety of pro re nata (PRN) intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) without a loading dose in the real-world setting. [5]

Received Intravitreal Brolucizumab

All patients received intravitreal brolucizumab as primary or switch therapy. [1] The woman with a known medical history of an allergy to tropicamide ophthalmic solution, received intravitreal brolucizumab injection for polypoidal choroidal vasculopathy OD. [2]

intravitreal brolucizumab injection

Case 2: An 82-year-old man who had neovascular age-related macular degeneration, received the first dose of intravitreal brolucizumab injection OD. [1] Purpose To assess the short-term efficacy and safety profile of intravitreal brolucizumab injection in Indian eyes with neovascular age-related macular degeneration (nAMD) under real-world conditions. [2] Recently, she had been switched to intravitreal brolucizumab injection. [3] To describe three Japanese cases of retinal vasculitis that occurred following intravitreal brolucizumab injections and the systemic and local steroid treatment administered. [4] The woman with a known medical history of an allergy to tropicamide ophthalmic solution, received intravitreal brolucizumab injection for polypoidal choroidal vasculopathy OD. [5]

intravitreal brolucizumab therapy

The aim of the present study was to determine the efficacy and safety of intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) in the real-world setting. [1] The present study aimed to determine the efficacy and safety of pro re nata (PRN) intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) without a loading dose in the real-world setting. [2]